Effects of in vivo and in vitro exposure to rhodamine dyes on mitochondrial function of mouse embryos

Rhodamine B, an organic environmental pollutant induces reproductive toxicity in parental and teratogenicity in F1 generation in vivo

This study investigated the reproductive toxicity of rhodamine B in zebrafish and its transgenerational effects on the F1 generation. In silico toxicity predictions revealed high toxicity of rhodamine B, mainly targeting pathways associated with the reproductive and endocrine systems. In vivo experiments on zebrafish demonstrated that rhodamine B exposure at a concentration of 1.5 mg/L led to significant impairments in fecundity parameters, particularly affecting females. Histopathological analysis revealed distinct changes in reproductive organs, further confirming the reproductive toxicity of rhodamine B, with females being more susceptible than males. Gene expression studies indicated significant suppression of genes crucial for ovulation in rhodamine B-treated female fish, highlighting hormonal imbalance as a potential mechanism of reproductive toxicity. Furthermore, bioaccumulation studies showed the presence of rhodamine B in both adult fish gonads and F1 generation samples, suggesting transgenerational transfer of the dye. Embryotoxicity studies on F1 generation larvae demonstrated reduced survival rates, lower hatching rates, and increased malformations in groups exposed to rhodamine B. Moreover, rhodamine B induced oxidative stress in F1 generation larvae, as evidenced by elevated levels of reactive oxygen species and altered antioxidant enzyme activity. Neurotoxicity assessments revealed reduced acetylcholinesterase activity, indicating potential neurological impairments in F1 generation larvae. Additionally, locomotory defects and skeletal abnormalities were observed in F1 generation larvae exposed to rhodamine B. This study provides comprehensive evidence of the reproductive toxicity of rhodamine B in adult zebrafish and its transgenerational effects on the F1 generation.

Rhodamine Conjugated Gelatin Methacryloyl Nanoparticles for Stable Cell Imaging

Fluorescent nanomaterials have been widely used in biological imaging due to their selectivity, sensitivity, and noninvasive nature. These characteristics make the materials suitable for real-time and in situ imaging. However, further development of highly biocompatible nanosystems with long-lasting fluorescent intensity and photostability is needed for advanced bioimaging. We have used electrospraying to generate gelatin methacryloyl (GelMA)-based fluorescent nanoparticles (NPs) with chemically conjugated rhodamine B (RB). The extent of conjugation can be controlled by varying the mass ratio of RB and GelMA precursors to obtain RB-conjugated GelMA (RB-GelMA) NPs with optimal fluorescent properties and particle size. These NPs exhibited superior biocompatibility when compared with pure RB in in vitro cell viability and proliferation assays using multiple cell types. Moreover, RB-GelMA NPs showed enhanced cell internalization and improved brightness compared with unconjugated RB. Our experiments demonstrate that engineered RB-GelMA NPs can be used as a biocompatible fluorescent label for bioimaging.

Developmental effects of sublethal mitochondrial injury in mouse oocytes

Mitochondrial dysfunction may be acquired or inherited by oocytes without detectable morphological abnormalities. This pathology may account for some examples of unexplained pregnancy loss in women following transfer of morphologically normal in vitro fertilization (IVF) embryos. The present study was intended to determine whether sublethal mitochondrial injury in mouse oocytes before IVF negatively affects pre- and postimplantation development, and to further define the latency of developmental compromise in relation to aberrant mitochondrial metabolism. Mature mouse oocytes were loaded with the mitochondrial fluorophore rhodamine-123 and photosensitized for 20 sec, a duration previously found to permit preimplantation embryo development to the blastocyst stage and so deemed "sublethal." This treatment resulted in some aberrations in cytoplasmic patterning of organelles, but did not inhibit zygote mitochondrial metabolism. Blastocyst development following IVF was not significantly inhibited following sublethal oocyte photosensitization; however, a decrease in trophectoderm cell numbers was observed relative to untreated controls. Following intrauterine transfer, blastocysts derived from sublethally photosensitized oocytes implanted but later aborted at a higher rate, formed fetuses with lower average weights, and, in rare cases, formed abnormal fetuses relative to controls. Photosensitization for more prolonged durations resulted in failed fertilization (2 min) and rapid oocyte degeneration (10 min). Therefore, photosensitization duration and the consequent degree of mitochondrial dysfunction are negatively related to the onset of developmental compromise. Acquired low-level mitochondrial injury is heritable by the resultant embryos and can cause postimplantation developmental compromise that may be relevant to some clinically observed outcomes following human assisted reproduction strategies, including reduced birth weights for gestational age. Future strategies for the detection and prevention of mitochondrial dysfunction may assist in improving outcomes for some clinically infertile women.

Effects of rhodamine 6G on the mitochondrial ultrastructure of mouse spermatocytes

Effects of rhodamine 6G on spermatocyte mitochondria were assessed in BALB/c mice in vivo. Four groups of mice were given rhodamine 6G doses of 0.0, 0.3 and 0.5 and 0.8 mg.kg-1.d-1 i.p. for 5 days. On the 5th day after the last day of dye administration, the mice were killed and testicular tissue was prepared for electron microscopy. Exposure to rhodamine 6G resulted in dose-dependent effects, primarily intracristal expansion of mitochondria.

Metabolism and elimination of rhodamine 123 in the rat

Little is known of the pharmacology of rhodamine 123 (RH-123), an agent reported to have carcinoma-selective experimental antitumor activity. Accordingly, using a high-performance liquid chromatographic assay system with fluorescence detection, we examined the plasma decay and the biliary and urinary elimination of parent drug and metabolites in female Sprague-Dawley rats receiving RH-123 at an intravenous dose (5 mg/kg) equivalent to the therapeutic dose used in murine tumor models. Following drug administration to unconscious animals, plasma levels of drug-associated fluorescence fell in a triphasic manner (t1/2 alpha, 15 min; t1/2 beta, 1 h; t1/2 gamma, 4.7 h). In plasma, unchanged drug predominated but lower levels of the deacylated metabolite rhodamine 110 (RH-110) and two unknowns were also detectable throughout the study. Drug fluorescence was recovered extensively in both urine and bile. In unconscious animals with ureteral cannulae, urinary excretion (11.4% of the dose in 6 h) occurred predominantly as unchanged RH-123 (97% of the total), with low levels of RH-110 (2.4%) and two unknowns (less than 0.6% combined) also being present. Similarly dosed conscious animals (without surgical intervention) housed in metabolic cages showed a comparable pattern of urinary excretion, with 11.9% of the drug dose being recovered in 6 h and 21.9%, by 48 h. Biliary drug elimination accounted for 8% of the delivered dose in 6 h in unconscious animals and for 11% by 36 h in conscious animals fitted with biliary cannulae. In contrast to urinary excretion, in which unchanged drug predominated, only 50% of the fluorescence recovered in bile was attributable to RH-123. The remainder was due to a number of products that were detectable throughout the study. Of these, one present at significant levels was identified as a glucuronide conjugate of RH-123, based on the liberation of parent drug when the purified metabolite was incubated with beta-glucuronidase or hydrolyzed with 1 N hydrochloric acid. Further studies with a radiolabeled form of RH-123 are necessary to establish the identity of the remaining unknowns disclosed in this work.